Julphar appoints new CEO to drive strategic growth

Julphar appoints new CEO to drive strategic growth

Ras Al Khaimah, UAE: Gulf Pharmaceutical Industries (Julphar or the Company), one of the largest pharmaceutical manufacturers in the Middle East and Africa, has announced the appointment of Mr. Basel Ziyadeh as Chief Executive Officer (CEO), as the company drives its transformational growth strategy across the Middle East region and beyond.

The Company has undergone significant changes in recent years, streamlining its activities by divesting from its non-core activities and focusing on its “Strategy 2030”. The strategy aims to deliver sustainable growth around six core pillars: maximizing revenue from its current product portfolio, new product launches, geographical expansion, strategic business initiatives, advanced specialty products initiatives, and inorganic growth initiatives. With a clear strategic direction in place and over 25 years of experience in the pharmaceutical industry, the new CEO, Mr. Basel is poised to continue this transformational journey and lead the company towards its vision of providing health solutions regionally and globally, while ensuring world-class care remains at the very heart of Julphar.

Mr. Basel Ziyadeh will succeed Dr. Essam Mohamed as CEO, who has stepped down from the role, having joined in 2020, with over 25 years working in the healthcare sector.

Sheikh Saqer Humaid Al Qasimi, Chairman of the Board at